Yes the interviewee incorrectly said Dimerix is moving from phase 1 to phase 2 when it's actually moving from phase 2a to phase 2b.
Commentators and ASX investors for many years have always been quick to point out the disparity between biotech valuations on the ASX and on the NASDAQ and the interviewee is suggesting that this may change now that some US companies are "scooping up stocks" here. Not licencing deals but 100% acquisitions
New drug "expected to hit the market within 2 years", page-9
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.015(4.05%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.3¢ | $442.1K | 1.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 256045 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 15870 | 3 |
View Market Depth
| Last trade - 13.11pm 05/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |